Showing results (101-110 of 118) with videos related to
Sort By:
Pageof 12
Open Medicine (Warsaw, Poland)|December 30, 2022
Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart blockChunhong Hu, Lishu Zhao, Chengzhi Zhou, et al.Thoracic Cancer|January 24, 2020
Management of immune checkpoint inhibitor-related adverse events: A review of case reportsXiaoyan Si, Peng Song, Jun Ni, et al.Biomarker Research|February 14, 2024
Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinomaNan Zhang, Xu Yang, Mingjian Piao, et al.Hepatobiliary Surgery and Nutrition|August 23, 2024
Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinomaYiran Li, Ziyu Xun, Junyu Long, et al.Journal for Immunotherapy of Cancer|June 6, 2024
Characterizations of multi-kingdom gut microbiota in immune checkpoint inhibitor-treated hepatocellular carcinomaChengpei Zhu, Chenchen Zhang, Shanshan Wang, et al.Lung Cancer (Amsterdam, Netherlands)|November 16, 2018
Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsyYan Xu, Min Hu, Meizhuo Zhang, et al.Thoracic Cancer|January 23, 2019
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303Xiaoyan Si, Li Zhang, Hanping Wang, et al.Therapeutic Advances in Medical Oncology|December 7, 2020
A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancerXiaoyan Si, Jinwan Wang, Ying Cheng, et al.Journal of Advanced Research|August 14, 2025
Gut microbiota and metabolite signatures predict severe immune-related adverse events in advanced hepatobiliary cancersChengpei Zhu, Dongya Zhang, Yunchao Wang, et al.Biomarker Research|June 3, 2024
Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancerChengpei Zhu, Yunchao Wang, Ruijuan Zhu, et al.Pageof 12